ALFA Finder| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 17% YoY growth, hitting 450 crore, primarily organic volume growth. |
|---|---|
| Margins | EBITDA margin expanded 210 bps to 25.2% due to efficiency. |
| Demand visibility | Strong structural shift toward organized diagnostics in smaller towns. |
| Management confidence | High; explicitly stating they exceeded guided revenue and margin targets. |
Growth
Revenue grew 17% YoY, primarily driven by a 10% increase in patient volumes rather than price hikes.
Outlook
Management guides for 14-15% revenue growth and 27-28% EBITDA margins over the next two years.
Risks
Potential margin dilution from aggressive tier-2/3 expansion and dependence on volatile seasonal illness cycles.
Last quarter's promises, checked
Delivered
- Guided 12-13% organic revenue growth → delivered 13.7% (= BEAT)
- Commitment to move Core Diagnostics to high-single-digit EBITDA → delivered high-single-digit (= BEAT)
- Guided organic revenue margins to pre-COVID levels (~26%) → delivered 25.9% (= BEAT)
Partly delivered
- Guided 3-year EBITDA margin target 27-28% → delivered 25.4% Group / 27.2% Organic Q4 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹574.70
- Market cap
- ₹11,927 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 53.2×Sector 54.5×
- Promoter holding
- 47.82%-1.04% QoQ
- FII holding
- 11.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Earnings Call Transcript: Key Takeaways
Metropolis delivered a robust 16% revenue growth, beating prior 12-13% organic guidance. Operating leverage is kicking in, with H1 margins expanding 190 bps despite heavy monsoon headwinds and no price hikes.
- Call
- Guides 16% growth
Metropolis Healthcare Dividend
Metropolis Healthcare declared an interim dividend of ₹1 per equity share for FY 26-27. The record date is 9 November 2026.
Metropolis Healthcare Results Update
Metropolis Healthcare posted Q2 FY27 revenue up 16% to ₹497 crore and PAT up 43% to ₹75 crore. Board declared a ₹1 per share interim dividend.
Metropolis Healthcare Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 497 Cr (+16% YoY), EBITDA INR 135 Cr at 27.2% margin, PAT INR 75 Cr (+43%). H1 revenue INR 947 Cr (+16%). Strategy is Metropolis 3.0, focused on tech, science and profitable growth.
Metropolis Healthcare Q2 FY27 Results: Net Profit ₹75.5 Cr, Up 42.7% YoY
Metropolis Healthcare Ltd reported revenue from operations of ₹496.8 Cr (+15.8% YoY) and net profit of ₹75.5 Cr (+42.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹75.5 Cr · +42.7% YoY
Metropolis Healthcare Employee Stock Options
Metropolis Healthcare granted 24,060 RSUs and 3,58,920 ESOPs under its 2025 plans, and allotted 65,600 shares under its RSU Plan 2020.